Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
T ype 2 diabetes is a complex meta-bolic disorder characterized byhyperglycemia arising from a com-bination of insufficient insulin secretion together with resistance to insulin action. The incidence and prevalence of type 2 diabetes are rising steadily, fuelled in part by a concomitant increase in the world-wide rates of obesity. As longitudinal studies of type 2 diabetes provide evi-dence linking improved glycemic control with a reduction in the rates of diabetes-associated complications, there is consid-erable interest in the therapy of type 2 diabetes (Fig. 1), with a focus on the de-velopment and use of new agents that ex-hibit improved efficacy and safety relative
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, it was implicated that GLP-1 analogue therapy increased the risk of acute pancreatitis, but subsequent studies using larger cohorts did not confirm this finding.8,267”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [267]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“Moreover, both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events.”
BackgroundInfluentialSelf-citationLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Intriguingly, the GLP-1 metabolite, GLP-1 (9–36), also exerts cardioprotective actions in preclinical studies through mechanisms independent of the known GLP-1R (14); hence, ongoing research is directed at understanding the complexity of incretin biology in the cardiovascular system and the potential for incretin-base…”
BackgroundSelf-citationNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Self-citationNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“The GLP-1R is expressed in cardiomyocytes and endothel ial cel ls , and preclinical studies demonstrate that GLP-1R activation is associated with substantial cardioprotect ion and reduced infarct s ize in experimental models of coronary artery ischemia (9,10).”
BackgroundSelf-citationRoman, S., Lin, R., & Sosa, J. A. (2006) · Cancer · doi:10.1002/cncr.22244 · Cited by 548
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Is Glycemic Control Improving in U.S. Adults?
Hoerger, T. J., Segel, J. E., Gregg, E. W., & Saaddine, J. B. (2008) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477
Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Steendijk, P., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 470
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Costante, G., Meringolo, D., Durante, C., Bianchi, D., Nocera, M., Tumino, S., Crocetti, U., Attard, M., Maranghi, M., Torlontano, M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1590 · Cited by 372
Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006
Cheung, B. M. Y., Ong, K. L., Cherny, S. S., Sham, P.-C., Tso, A. W. K., & Lam, K. S. L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.047 · Cited by 348
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · cited 1×
“prevention of incretin degradation, leading to potentiation of GLP-1 and GIP action (6).”
BackgroundSelf-citationRachman, J., Barrow, B. A., Levy, J. C., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 269
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · cited 1×
“(23) detected histological evidence for acinar inflammation, cell drop-out and possible fibrosis and increased levels of serum lipase in SpragueDawley rats treated with exendin-4 for 75 Figure 2—Comparison of features associated with exenatide twice daily versus the properties of the emerging class of long-acting GLP-…”
BackgroundChilcott, J. B., Tappenden, P., Jones, M. L., & Wight, J. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80078-8 · Cited by 162
Koehler, J. A., Baggio, L. L., Lamont, B. J., Ali, S., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db09-0626 · Cited by 159
Self-citationExenatide and Rare Adverse Events
(2008) · New England Journal of Medicine · doi:10.1056/nejmc0707137 · Cited by 135
Exenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 122
LiVolsi, V. A. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3707 · Cited by 118
Garlick, R. L., Mazer, J. S., Higgins, P. J., & Bunn, H. F. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110856 · Cited by 111
Routine serum calcitonin measurement in the evaluation of thyroid nodules
Elisei, R. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.008 · Cited by 98
Marzioni, M., Alpini, G., Saccomanno, S., Candelaresi, C., Venter, J., Rychlicki, C., Fava, G., Francis, H., Trozzi, L., Glaser, S., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.007 · Cited by 96 · cited 1×
“As GLP-1R agonists may also affect smooth muscle responses and may regulate cholangiocyte function (25), their effects on the biliary tract and gallstone formation should also be examined.”
BackgroundBan, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 88
Self-citationType 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 76
Self-citationLamari, Y., Boissard, C., Moukhtar, M. S., Jullienne, A., Rosselin, G., & Garel, J.-M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00895-2 · Cited by 73
Crespel, A., De Boisvilliers, F., Gros, L., & Kervran, A. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756532 · Cited by 67
Verga, U., Ferrero, S., Vicentini, L., Brambilla, T., Cirello, V., Muzza, M., Beck‐Peccoz, P., & Fugazzola, L. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0053 · Cited by 41
Research works printed but not linked: 2
- Horner, SEER Cancer Statistics Review, 1975–2006 [Internet], 2009
- Parola, 2009, FDA Advisory Committee Nonclinical Briefing Document, NDA, 22
Cited by
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Metadata
- Authors
- Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B.
- Affiliations
- University of Toronto (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Yale University (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-02-01
- Volume
- 33
- Issue
- 2
- Pages
- 428-433
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2809297
- OpenAlex
- W2134760433
- Cited by
- 316
- References
- 40
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 15 · 2020: 11 · 2019: 17 · 2018: 17 · 2017: 15 · 2016: 20 · 2015: 24 · 2014: 28 · 2013: 33 · 2012: 31
- FWCI
- 28.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- V Foundation for Cancer Research
- Park Nicollet Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Exelixis
- Insulet Corporation
- MannKind Corporation
- ResMed
- Eisai
- Novo Nordisk
- Plexxikon
- National Institutes of Health
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007017)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, glycemic control, insulin resistance, insulin secretion, diabetes complications, drug safety, obesity
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Drug Administration Schedule, Humans, Hypoglycemic Agents, Peptides, Venoms, Incidence, Prevalence, Treatment Outcome, Risk Assessment, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.